89bio, Inc. (ETNB)
NASDAQ: ETNB · Real-Time Price · USD
10.49
-0.16 (-1.50%)
At close: Jul 18, 2025, 4:00 PM
10.59
+0.10 (0.95%)
After-hours: Jul 18, 2025, 5:16 PM EDT
Company Description
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases.
Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia.
The company was founded in 2018 and is headquartered in San Francisco, California.
89bio, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Nov 11, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 93 |
| CEO | Rohan Palekar |
Contact Details
Address: 655 Montgomery Street, Suite 1500 San Francisco, California 94111 United States | |
| Phone | 415 432 9270 |
| Website | 89bio.com |
Stock Details
| Ticker Symbol | ETNB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001785173 |
| CUSIP Number | 282559103 |
| ISIN Number | US2825591033 |
| Employer ID | 83-1114349 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Rohan Palekar | Chief Executive Officer and Director |
| Ryan Stephen Martins | Chief Financial Officer |
| Francis W. Sarena | Chief Operating Officer |
| Quoc Le-Nguyen | Chief Technical Officer |
| Dr. Harry Mansbach M.D. | Chief Medical Officer |
| Shiva K. Natarajan CPA | Senior Vice President of Finance and Principal Accounting Officer |
| Annie J. Chang M.B.A. | Vice President of Investor Relations and Corporate Communications |
| Amanda Kurihara | Vice President of People and Culture |
| Melissa Abel | Senior Vice President of Commercial Strategy |
| Michael Baldwin | Senior Vice President and Head of Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 15, 2025 | 144 | Filing |
| May 30, 2025 | 8-K | Current Report |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 14, 2025 | SCHEDULE 13G/A | Filing |
| May 2, 2025 | SCHEDULE 13G/A | Filing |
| May 2, 2025 | 10-Q | Quarterly Report |
| May 1, 2025 | 8-K | Current Report |
| Apr 15, 2025 | ARS | Filing |
| Apr 15, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |